Advances in allergy management

Evaluation of relationship of inhaler technique with asthma control and quality of life

INTRODUCTION

There is a need to assess erroneous steps in the use of inhaler devices in people who have asthma. The objectives of this study were to assess the inhaler technique in patients who have asthma, the factors affecting improper technique, and the association of inhaler use with asthma control, hospital visits, and quality of life (QOL) of patients who have asthma.

METHODS

It was an observational, prospective, cross-sectional study conducted on patients with bronchial asthma. Patients were enrolled in the study; their history was recorded and they were asked to use inhaler in the presence of an investigator and the technique was scored. Asthma control and QOL of patients were assessed using asthma control questionnaire and Mini Asthma QOL questionnaire.

RESULTS

A total of 330 patients completed the study. Nearly 36.6% of the patients performed the steps incorrectly. Breathing normally for 30-60 min postinhaler use was the most common step done incorrectly. Patients with poorly controlled asthma (P < 0.001) and those with predicted forced expiratory volume at 1 s <70% performed the steps erroneously (P < 0.001).

CONCLUSION

All patients, particularly those above 40 years, should be given proper instructions regarding inhaler use to obtain therapeutic advantage.

Serum Leptin Levels in Patients with Allergic Rhinitis

OBJECTIVE: To investigate the serum leptin levels in patients with allergic rhinitis during the symptomatic period.

STUDY DESIGN AND SETTING: A randomized, prospective study was performed on 26 adult patients with allergic rhinitis and 20 control subjects with similar age, sex and body mass index in a tertiary otolaryngology center.

RESULTS: Leptin levels were 28.8 ± 14.1 ng/mL in the patients with allergic rhinitis, and 20.8 ± 13.5 ng/mL in the control group respectively. The difference between the groups was statistically significant (p = 0.04).

CONCLUSION: Serum leptin levels were found to be significantly higher in patients with allergic rhinitis in symptomatic period.

SIGNIFICANCE: Apart from its primary role in the regulation of body weight and energy expenditure, leptin may have a role in the inflammatory process of the allergic rhinitis.

Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old

BACKGROUND

The safety of fexofenadine has been examined extensively in adults and school-age children. However, the safety of fexofenadine in children younger than 6 years has not been reported to date.

OBJECTIVE

To compare the safety and tolerability of twice-daily fexofenadine hydrochloride, 30 mg, and placebo in preschool children aged 2 to 5 years with allergic rhinitis.

METHODS

This was a multicenter, double-blind, randomized, placebo-controlled, parallel-group study, conducted between February 29, 2000, and June 14, 2001. Participants were randomized to either fexofenadine hydrochloride, 30 mg, or placebo twice daily for a 2-week period. To facilitate dosing, capsule content was mixed with applesauce (approximately 10 mL). Safety assessments depended on date of entry into the study because of an amendment to the protocol. Before the amendment, assessments included physical examination, vital signs reporting (oral temperature, heart rate, and respiratory rate), and adverse event (AE) reporting. After the amendment, safety assessments included laboratory testing (blood chemistry and hematology profiles), physical examination, 12-lead electrocardiography, and vital signs (oral temperature, blood pressure, heart rate, and respiratory rate) and AE reporting.

RESULTS

Treatment-emergent AEs were observed in 116 of 231 participants receiving placebo and 111 of 222 receiving fexofenadine. These AEs were possibly related to study medication in 19 (8.2%) and 21 (9.5%) of the participants receiving placebo and fexofenadine, respectively, and most frequently involved the digestive system. No clinically relevant differences in laboratory measures, vital signs, and physical examinations were observed.

CONCLUSIONS

The findings show that fexofenadine hydrochloride, 30 mg, is well tolerated and has a good safety profile in children aged 2 to 5 years with allergic rhinitis.

Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen

BACKGROUND

Fluticasone furoate is a new enhanced-affinity glucocorticoid with a unique combination of pharmacodynamic and physicochemical properties suitable for topical activity.

METHODS

In this multicentre, randomized, double-blind, placebo-controlled, parallel-group study, patients [adults and adolescents >or=12 years of age with seasonal allergic rhinitis (SAR)] received once-daily (od) treatment for 2 weeks with either fluticasone furoate nasal spray 110 microg (n = 141) or placebo nasal spray (n = 144) administered in a unique, side-actuated device. Efficacy measures included total nasal symptom score (TNSS) and total ocular symptom score (TOSS). Patients also reported their overall response to therapy and rated their quality of life using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

RESULTS

Fluticasone furoate significantly improved the mean change from baseline in daily reflective TNSS compared with placebo (treatment difference of -1.757; P < 0.001). Fluticasone furoate was also significantly more effective in improving the morning predose instantaneous TNSS (treatment difference of -1.898; P < 0.001) and daily reflective TOSS (treatment difference of -0.741; P = 0.001). A significant treatment effect was observed as early as day 1. Compared with placebo-treated patients, fluticasone furoate-treated patients showed significantly greater improvements in overall evaluation of response to therapy (P < 0.001), as well as in overall RQLQ score (P < 0.001). Fluticasone furoate was well tolerated.

CONCLUSION

Fluticasone furoate nasal spray 110 mug od was effective in improving the nasal symptoms of SAR. It also produced significant improvements in ocular symptoms.

Quality of life and polysensitization in young men with intermittent asthma

BACKGROUND

Health-related quality of life (HRQoL) represents an important variable in asthma management. To date, to our knowledge, no study has explored the relationship between HRQoL and sensitization in patients with asthma.

OBJECTIVE

To evaluate the relationships among HRQoL and sensitization, pulmonary function, and bronchial hyperreactivity in a group of young men with intermittent asthma.

METHODS

We studied 185 conscripts with intermittent asthma and bronchial hyperreactivity. The Asthma Quality of Life Questionnaire was used. Skin prick testing, spirometry, and methacholine challenge were performed in all participants.

RESULTS

The Asthma Quality of Life Questionnaire median scores were greater than 4, indicating suboptimal HRQoL. Polysensitization was significantly associated with the worst HRQoL, whereas pulmonary function and bronchial hyperreactivity category were not.

CONCLUSIONS

This study provides the first evidence that HRQoL is associated with polysensitization in intermittent asthma and underlines the importance of evaluating this issue when managing young patients with slight respiratory symptoms.

Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique

BACKGROUND

Desloratadine is a selective H1-antihistamine used in the treatment of allergic rhinitis and chronic idiopathic urticaria. Desloratadine inhibits the release of allergic inflammatory mediators in vitro. We studied the impact of desloratadine on mast cell degranulation due to activation and re-activation by the secretagogue, compound 48/80.

METHODS

Rat peritoneal eluate containing 5-6% mast cells were activated by a low concentration of compound 48/80 in a medium containing the vital fluorescent dye, Sulforhodamine-B (SFRM-B, 200 microg/ml), which is engulfed by activated mast cells. The fluorescent image of activated mast cells was captured digitally and the total fluorescent area was analyzed when desloratadine was applied before or after compound 48/80.

RESULTS

Mast cells were not activated by desloratadine (10(-4) M), SFRM-B (200 microg/ml), or diluent alone. A low concentration of compound 48/80 (0.125 microg/ml) induced fluorescence, while mast cells lost fluorescent images due to further degranulation on re-exposure to compound 48/80. Desloratadine (10(-8)-10(-4) M), inhibited compound 48/80-induced mast cell degranulation in a concentration-dependent manner. Desloratadine also reduced the loss of fluorescent images due to re-exposure to compound 48/80.

CONCLUSIONS

Desloratadine may have a mast cell stabilizing effect at low concentrations in response to repeated mast cell activation in vitro.